Overview : Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 25, 2025

Read Press Release

Piper Sandler 3rd Annual Virtual Obesity Symposium

June 26, 2025 • 10:00 am ET

Q1 2025

Quarterly Results

Mar 31, 2025

PDF HTML

Earnings Release

PDF HTML

10-Q

HTML

Financials

ZIP XLS HTML

XBRL

Symbol

Nasdaq: CRBP

Price

Change

MKT Cap

Volume

Corbus is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline encompasses two different approaches to oncology with different risk profiles: a next-generation Nectin -4 Antibody Drug Conjugate (ADC) and monoclonal antibodies that target integrins to inhibit activation of TGFβ. Corbus is headquartered in Norwood, Massachusetts.

Yuval Cohen, Ph.D.

Chief Executive Officer, Director

Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Dr. Cohen has a Ph.D., summa

Dr. Dominic Smethurst, MA MRCP

Chief Medical Officer

Dr. Smethurst, MA MRCP, joined Corbus as our Chief Medical Officer in February 2024. He has over twenty years of experience working with various pharmaceutical and biotechnology companies, clinical research institutions, and the

Sean Moran, CPA, MBA

Chief Financial Officer

Sean Moran, CPA, joined Corbus as a co-founder and Chief Financial Officer in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery, and medical device companies. Mr. Moran

Ian Hodgson, Ph.D.

Chief Operating Officer

Dr. Hodgson joined Corbus in 2022 as Head of Clinical Operations and was promoted to Chief Operating Officer in March 2025. He has over 25 years of senior experience in drug development and operations across biotech, large

Christina Bertsch

VP of Human Resources

Christina Bertsch joined Corbus in April 2020. She has over 25 years of experience in human resources as both a management consultant and as an HR executive, primarily in the life sciences industry. Ms. Bertsch has significant

Rachelle Jacques

Chairman of the Board

Rachelle Jacques has more than 25 years of leadership experience across CEO, commercial, financial, and operational roles and has a strong track record of success advancing and launching transformative therapies. Jacques also serves on the View Full Bio

Alan Holmer

Director

Alan F. Holmer served from 1996 to 2005 as President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the worldwide interests of leading pharmaceutical and View Full Bio

Yuval Cohen, Ph.D.

Chief Executive Officer, Director

Anne Altmeyer, Ph.D.

Director

Dr. Altmeyer is currently the President and CEO of TigaTx, Inc. She previously served as the Chief Business Officer of Sigilon Therapeutics and Adicet Bio. Dr. Altmeyer also held roles of increasing responsibility in corporate development View Full Bio

Yong Ben, M.D., MBA

Director

Dr. Ben has over 25 years of medical experience in academia and pharmaceutical and biotech companies, including clinical practice, drug discovery and development in oncology and hematological malignancies. He is currently Chief Medical View Full Bio

John Jenkins, M.D.

Director

Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency View Full Bio

Winston Kung, MBA

Director

Winston Kung currently serves as Chief Financial Officer of Arrivent BioPharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics. Prior to Arrivent, Mr. Kung was Chief View Full Bio

Latest News

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Upcoming Event

Piper Sandler 3rd Annual Virtual Obesity Symposium

Latest Financial Results

Q1 2025

Stock Information

Symbol

Price

Change

MKT Cap

Volume

Company Overview

Officers & Directors

Yuval Cohen, Ph.D.

Dr. Dominic Smethurst, MA MRCP

Sean Moran, CPA, MBA

Ian Hodgson, Ph.D.

Christina Bertsch

Rachelle Jacques

Alan Holmer

Yuval Cohen, Ph.D.

Anne Altmeyer, Ph.D.

Yong Ben, M.D., MBA

John Jenkins, M.D.

Winston Kung, MBA

Overview

Latest News

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Upcoming Event

Piper Sandler 3rd Annual Virtual Obesity Symposium

Latest Financial Results

Q1 2025

Stock Information

Symbol

Price

Change

MKT Cap

Volume

Company Overview

Sign up for email alerts

Officers & Directors

Yuval Cohen, Ph.D.

Dr. Dominic Smethurst, MA MRCP

Sean Moran, CPA, MBA

Ian Hodgson, Ph.D.

Christina Bertsch

Rachelle Jacques

Alan Holmer

Yuval Cohen, Ph.D.

Anne Altmeyer, Ph.D.

Yong Ben, M.D., MBA

John Jenkins, M.D.

Winston Kung, MBA